Skip to main content

Hoffman Reid's Form 4 filing

Vor Biopharma Inc. (VOR) · filed Oct 21, 2025

Accession no.
0002050755-25-000019
Filed
Oct 21, 2025, 5:45 PM ET
Trade date
Oct 17-21, 2025
Filing delay
4 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions. Open-market sales total $1.13M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hoffman ReidCIK 000151933910% Owner
Reprogrammed Interchange LLCCIK 000205075510% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Oct 17, 2025Common StockSSaleDisposed−24,689$30.22F1−$746,118.861,179,753Direct
Oct 17, 2025Common StockSSaleDisposed−1,028$31.00−$31,8681,178,725Direct
Oct 20, 2025Common StockSSaleDisposed−11,616$30.05F3−$349,101.461,167,109Direct
Oct 21, 2025Common StockSSaleDisposed−200$30.08−$6,0151,166,909Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

This transaction was executed in multiple trades at prices ranging from $30.00 to $30.88. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F3

This transaction was executed in multiple trades at prices ranging from $30.00 to $30.27. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)